Application 1087
Brain natriuretic peptide assays in the diagnosis and monitoring of heart failure
Application No. | 1087 |
| Application Name | Brain natriuretic peptide assays in the diagnosis and monitoring of heart failure |
| Advisory Panel | Professor Syd Bell (Chair and MSAC member) Dr Debra Graves (MSAC member) Professor Julia Potter (Royal College of Pathologists of Australasia nominee) Ms Paula Calcino (Consumers' Health Forum of Australia nominee) Dr David Sullivan (Cardiac Society of Australia and New Zealand nominee) Dr Jenny Doust (Royal Australian College of General Practitioners nominee) Dr John Beilby (Australasian Association of Clinical Biochemists nominee) |
| Date Received by MSAC Secretariat | 22 July 2004 |
| Stage 1 - Eligibility | Eligible |
| Stage 2 - Assessment | Completed |
| Stage 3 - Formulation of Advice to the Minister | This assessment was considered by the MSAC at the 15 November 2006 meeting. Part A - Brain natriuretic peptide assays in the diagnosis and monitoring of heart failure in the hospital setting MSAC has considered the safety, effectiveness and cost effectiveness of the use of assays of brain natriuretic peptides (BNP) in the diagnosis of heart failure in patients presenting with dyspnoea in the hospital emergency setting and the use of the assays in monitoring the progress of patients with heart failure. MSAC finds that there is sufficient evidence of the safety, effectiveness and cost effectiveness of the use of these assays in the diagnosis of heart failure but insufficient evidence of effectiveness and cost effectiveness for their use in monitoring the progress of patients with heart failure. MSAC recommends that public funding be provided for the use of assays of BNP in the diagnosis of heart failure in the hospital emergency setting. Part B - Brain natriuretic peptide assays in the diagnosis and monitoring of heart failure in the primary care setting MSAC has considered the safety, effectiveness and cost effectiveness of the use of assays of B-type natriuretic peptides in the diagnosis of heart failure in patients presenting with dyspnoea in the non-hospital setting when compared with current clinical practice +/- echocardiography. MSAC finds that there is sufficient evidence that B-type natriuretic peptide assays, when used in the diagnosis of heart failure in patients presenting with dyspnoea, are safe and effective (diagnostically accurate). MSAC finds that there is major uncertainty around the cost effectiveness in the non - hospital setting. MSAC recommends that public funding is not supported for the use of assays of B-type natriuretic peptides in the diagnosis of heart failure in patients presenting with dyspnoea in the non-hospital setting at this time. MSAC further recommends research on the use of BNP in the general practice setting to identify appropriate usage and the patient group most likely to benefit in the non hospital setting. |
| Stage 4 - Decision | Part A - Endorsed by the Minister for Health and Ageing on 5 February 2007 Part B - Endorsed by the Minister for Health and Ageing on 29 August 2007 |
| Stage 5 - Implementation | Implemented |
